🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — October 30, 2026

The October 30, 2026 Mega Contracts Monitor captured a single $100M+ award: a $226,106,338 firm-fixed-price delivery order to Signature Choice III, LLC from the Department of Veterans Affairs (Strategic Acquisition Center Fredericksburg) for VA Claims and Customer Services under NAICS 524114, with a base-plus-options ceiling of $418,223,061. The award is 100% civilian — zero defense-related obligations — so it carries no DOD, NDAA, or defense-prime read-through; the dominant theme is VA claims-processing and health insurance administration outsourcing to a Service-Disabled Veteran-Owned Small Business. The highest-conviction signal is the scale of the vehicle ($192.1M of unexercised option value above the obligation) rather than any immediate revenue recognition, since Total Outlayed stands at $0. The key risk is that the award was NOT COMPETED with no set-aside designation despite the recipient's SDVOSB status, creating protest and re-competition exposure, compounded by medium pricing risk on a firm-fixed-price structure. Direct equity exposure is nil — Signature Choice III is a private Oklahoma City LLC — so the digest is a sector read-through, not an investable security call.

1 total filings
· daily

High-Value Federal Grants ($5M+) — October 30, 2026

This $741.2M, 8-award stream is entirely civilian (0/8 defense-related), dominated by HHS/CMS Medicare quality-improvement and management-consulting delivery orders (~$308.5M across HSAG, TMF, Health Quality Innovators, and Telligen) plus a $226.1M non-competed VA claims/customer-services order to Signature Choice III. The single highest-conviction investable read-through is Tutor Perini's subsidiary Perini Management Services winning a $69.5M firm-fixed-price National Park Service water/wastewater rehabilitation contract in Death Valley (bullish, but $0 outlayed and a forward-dated 2026-07-20 award). SAIC's $66.6M GSA ClearPath mainframe-hosting delivery order is the only other public-equity-linked award, though anomalous data (53 subawards totaling $126.4M exceeding the prime value; negative outlayed of -$65,728) limits confidence. Key risk: most of the stream is low-margin cost-plus-fixed-fee work held by private nonprofits/LLCs with minimal outlay to date (e.g., Signature Choice $0 outlayed, HSAG 81.5% unfunded), so near-term cash realization and option exercises—not headline obligations—will determine actual revenue.

8 total filings
· daily

General Federal Contracts — October 30, 2026

This digest covers 8 federal contracts totaling $741.2M, all civilian with zero defense-related awards. The dominant theme is CMS/HHS spending on Medicare quality and management consulting, with four cost-plus-fixed-fee awards to nonprofits and private firms (HSAG, TMF, Health Quality Innovators, Telligen) totaling $308.5M, plus a $226.1M VA claims processing award to Signature Choice III. The highest-conviction signal is the VA award to Signature Choice III, which carries a $418.2M ceiling and is not competed, though $0 has been outlayed. The only public-equity read-throughs are Tutor Perini's $69.5M National Park Service water infrastructure contract (bullish) and SAIC's $66.6M GSA mainframe hosting delivery order (neutral, with anomalous subaward data). Key risk: most awards are cost-plus-fixed-fee with low outlay to date, limiting near-term revenue visibility, and the VA award's non-competitive nature could invite protest.

8 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 30, 2026

Today's S&P 500 Technology filings present a bifurcated picture: Fortinet delivered a standout Q3 2026 with revenue up 20.5% YoY to $2,078.4M and product revenue surging 36.8%, yet gross margin compressed (product GM 64.4% vs 67.7%) and buyback intensity slowed to $972.8M from $2,232.6M a year ago. Meanwhile, insider activity skews cautious-to-bearish: Texas Instruments director Ronald Kirk sold 6,065 shares at $310.39 (~$1.88M) after exercising options at $79.26, and Datadog CTO Alexis Le-Quoc sold 11,430 shares at $277.30 (~$3.17M) under a 10b5-1 plan amid 11 total transactions. Palantir disclosed three separate stock awards to executives (Taylor, Glazer, Sankar) totaling 987,246 Class A shares, a neutral but dilution-relevant governance signal. The common thread is a sector investing heavily for growth (Fortinet product acceleration, Palantir talent retention via equity) while insiders at mature names monetize gains. Portfolio implication: favor names with accelerating product revenue and disciplined capital returns; monitor insider selling clusters in semis and high-multiple software.

3 high priority 3 medium 6 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 30, 2026

Across 11 NASDAQ-100 filings, the dominant theme is a widening gap between operating momentum and bottom-line optics: Amazon, Intel, and Gilead all posted strong top-line and/or operating gains that were masked by non-operating items, mark-to-market losses, or acquired IPR&D charges. Amazon's Q3 revenue rose 12.1% YoY to $201.9B with operating income up 61.2% to $28.1B, yet EPS slipped to $1.89 on a $703M non-operating expense versus a $10.2B prior-year gain; capex is running at a $215B trailing-12-month pace, funded by $115.1B of nine-month debt proceeds. Intel delivered 20.9% YoY revenue growth and a swing to $2.5B operating income, but a $12.6B mark-to-market loss on Escrowed Shares drove a nine-month net loss of $11.4B, while Foundry remains loss-making at -$1.85B. Gilead's product sales grew 12.9% but $11.3B of acquired IPR&D and $1.75B of impairments produced a nine-month net loss of $6.0B and cut retained earnings to $3.1B from $13.7B. ADP showed solid 6.1% revenue and 13.7% EPS growth, offset by a $855M unrealized AFS loss that crushed comprehensive income 60.8%. Insider activity skewed negative: sales at CoreWeave (PAO, $392K), Texas Instruments (director, $1.88M), Alphabet (director, $23K), and PayPal (10b5-1, $40.5K), while Palantir issued large equity awards to three executives (987K shares combined) with no open-market purchases. The common thread is elevated capital intensity and non-operating volatility across mega-cap tech and biopharma, with insider conviction tilted toward selling into strength.

6 high priority 5 medium 11 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — October 30, 2026

The October 30, 2026 filing batch is dominated by Vanguard's routine 13G/A updates, with 46 of 50 filings representing passive index positions, many clustered just below the 5% threshold (4.92-4.99%) as Vanguard manages disclosure obligations across a $9T+ AUM platform. The most material developments are event-driven: Maplebear's (Instacart) merger with DoorDash triggered a Sequoia Capital voting agreement covering 18.6M shares (7.9%), while Yorkville's 13D on Ives Ultra AI reveals activist intent to push for a sale. Karpus Management continued aggressive accumulation of Western Asset Inflation-Linked Income Fund, now at 38.82% ownership, signaling a potential control contest at the closed-end fund. Quint Digital's 14.38% stake in Lee Enterprises, backed by a 10b5-1 purchase plan, sets up a potential board representation fight, while Prescott's 13D/A on World Acceptance shows a modest 88K share sale back to the issuer but maintains a 26.6% controlling stake. Across the batch, insider activity is minimal, but the presence of multiple 13D filings with activist language (Yorkville, Quint, Karpus) suggests a pickup in shareholder engagement activity heading into year-end.

7 high priority 43 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 30, 2026

The October 30, 2026 S&P 500 Financials filings reveal a sector navigating a mixed operating environment: Bank of America posted solid top-line growth (Q3 revenue +3.2% YoY to $29,958M, NII +8.0%) but suffered a sharp 16.8% YoY net income decline to $6,933M as noninterest expense surged 13.8% and the efficiency ratio deteriorated to 65.83% from 59.70%. Capital markets activity was robust, with American Express issuing $3.0B in senior notes (coupons 5.447%–5.817%) and U.S. Bancorp raising $1.0B via Series P preferred stock, signaling continued balance-sheet optimization and funding diversification. Insider activity was negative: Robinhood Markets sold 124,319 shares (~$3.08M) of Robinhood Ventures Fund I, trimming its stake to 12.92M shares. Truist's 13F-HR disclosed 5,371 positions with a large-cap tilt (Coca-Cola Europacific Partners $479.2M, Eaton $209.8M), offering little actionable signal. Overall, the filings point to margin pressure from elevated operating costs, resilient net interest income, and active capital management, with investors likely to focus on expense discipline and credit trends in upcoming earnings calls.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Energy Sector SEC Filings — October 30, 2026

Q3 2026 earnings from ExxonMobil and Chevron reveal a sector enjoying a powerful YoY upcycle—Exxon YTD earnings surged +$11.8B and Chevron's ROCE more than doubled to 17.7%—yet sequential momentum is already fading as lower realizations, entitlement effects, and Middle East disruptions bite. Exxon's Upstream earnings fell to $7.088B from $7.927B QoQ and Chemical Products dropped to $735M from $1.131B, while Chevron's earnings declined 18% QoQ and production slipped 2.6% YoY to 3,980 MBOED. Capital returns remain the anchor: Exxon declared its 44th consecutive annual dividend increase at $1.07/share, and Chevron held its $1.78/share dividend while cutting leverage (debt-to-CFFO 0.6x vs 1.3x). Portfolio actions are accelerating—Exxon raised working interests in Papua LNG (34%) and Rovuma (50%), and Valero agreed to buy a 700-acre former LyondellBasell refinery site for $320.5M, signaling bet-on-refining capacity. Insider and institutional flows are mixed: SLB's Chief Legal Officer sold ~$1.12M of stock, Kinder Morgan's President gifted shares, and Vanguard disclosed large passive stakes across Exxon (7.62%), Halliburton (5.36%), TPL (5.11%), and SLB (4.97%). Net read: a sector at peak YoY optics but decelerating sequentially, where capital discipline, M&A optionality, and dividend durability are the differentiators.

2 high priority 7 medium 9 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 30, 2026

The 9 filings from S&P 500 Consumer Staples constituents reveal a sector navigating a bifurcated demand environment, with organic growth diverging sharply from reported sales due to portfolio actions and foreign exchange. Church & Dwight delivered a standout Q3 with organic sales +5.1% and adjusted EPS +13.6%, yet reported sales grew only 1.0% and Q4 is guided to decline ~0.5% due to 2025 strategic portfolio actions, highlighting the gap between underlying momentum and headline numbers. Colgate-Palmolive posted organic growth of 3.6% and raised full-year EPS guidance to 5-7%, but North America net sales fell 1.7% with volume down 3.7% and operating profit down 11%, signaling regional weakness. Margin expansion was a common theme: Church & Dwight gross margin +170 bps to 46.8% and Colgate +80 bps to 60.2%, driven by cost controls and pricing. However, cash flow trends are mixed: Church & Dwight operating cash flow slipped 1.3% on a $98.2M inventory build, while Colgate's operating cash flow rose 6.1% but comprehensive income fell 9.1% on currency headwinds. Insider activity is absent, but Vanguard's passive stakes (4.61-7.05%) in General Mills, Molson Coors, and Estée Lauder reflect continued institutional interest without control intent. P&G's $4.0B debt offering at coupons up to 5.900% signals a higher-for-longer rate environment, raising the bar for capital allocation. Overall, the sector shows resilient pricing power and margin recovery, but volume pressures and currency headwinds warrant selective exposure.

2 high priority 7 medium 9 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 30, 2026

The 15 filings in this digest reveal a bifurcated S&P 500 Industrials landscape: defense and aerospace names (General Dynamics) are posting double-digit revenue growth with record backlog, while transportation and business-services names (Republic Services, ADP) are growing mid-single-digits but facing margin and cash-flow pressures. General Dynamics stands out with Q3 2026 revenue +12.9% YoY to $14.6B and EPS +15.7% to $4.49, yet free cash flow fell to $1.2B from $1.9B and Combat Systems margin contracted 110 bps, underscoring execution unevenness. Republic Services grew revenue 8.2% YoY to $4,559M but saw interest expense +9.8% and equity-method losses widen to $48M, while ADP grew revenue 6.1% but suffered a 60.8% collapse in comprehensive income on an $855M unrealized securities loss. Insider activity skews negative: Delta's CEO sold $4.1M, UPS's Chief US Domestic Officer sold $877K, and FedEx's Chief People Officer sold $7.31M across 14 transactions. Parker-Hannifin's eight directors each received 205 RSUs, a routine but broad-based board compensation event. The dominant cross-cutting theme is cash-flow quality and balance-sheet strain (FX translation losses at GD, AOCI widening at ADP, receivables build at Republic) even as top-line growth remains intact.

14 high priority 1 medium 15 total filings
· daily

US Material Events SEC 8-K Filings — October 30, 2026

The October 30, 2026 filing batch is dominated by corporate control events and liquidity actions: a take-private merger nearing its November 13 shareholder vote (Utz), a completed Chapter 11 asset sale to Teva (BioXcel), a related-party liquidation of an operating business (Zoned Properties), and a license-for-equity deal that cedes control of a U.S. microcap to Pluri. Leadership churn is unusually dense—at least 12 officer/director changes—including four simultaneous role vacancies at LiveOne/PodcastOne and a disputed CEO resignation at Visium tied to a sweeping financial-restatement certificate covering FY2016–FY2026. Capital-markets activity skews toward dilution and balance-sheet repair: PIPEs and registered directs at Koil ($5.6M), OpenWorld ($3.5M), ADM Tronics ($1.55M), Pluri ($1.0M), plus ATM capacity at Porch (15M shares) and a $100M equity line terminated in exchange for dilutive stock at Olenox. Period comparisons show a sharp bifurcation: Carter's delivered 91.7% GAAP operating-income growth on a 0.7% sales decline but guided FY2026 EPS down high-single to low-double digits, while Koil posted ~48–57% YoY Q3 revenue growth yet held only $0.6M of cash pre-raise. Debt markets were active and constructive—Main Street ($500M at 6.55%) and Franklin BSP ($300M at 7.25%) term out liabilities, and NCL locked ~$5.0B of SACE-backed export-credit financing for 2034/2036 vessels—signaling ample but increasingly selective credit access.

50 high priority 50 total filings
· daily

Insider Trading Pulse — October 30, 2026

Today's insider tape is dominated by a broad wave of equity awards and option grants (Spruce Power, Jaguar Uranium, Regis, Ventas, FuelCell, Shutterstock, Omeros, D-Wave, Capstone, Gain Therapeutics, Actuate) that signal board-level compensation activity rather than open-market conviction. Against that neutral backdrop, the most actionable signals are a cluster of discretionary and 10b5-1 sales: Delta CEO Ed Bastian sold 50,000 shares (~$4.1M), Porch Group saw its CFO and a director sell ~$1.05M combined, CoreWeave's PAO sold ~$392K post-option exercise, and Carnival, Impinj, Zoom, PagerDuty, ACADIA, Trupanion, Landmark, Bridgewater and New ERA insiders all trimmed. The standout bullish datapoint is Rapport Therapeutics director James Healy's ~$20M open-market purchase at $21.00, a rare high-conviction buy in a tape otherwise skewed to sales. Rivian CFO Claire McDonough's disposal of 730,292 shares to the issuer (leaving only 88,886 held) is a material ownership reduction worth flagging. Saba Capital continues its activist-style accumulation in closed-end funds (Gabelli Healthcare, Ellsworth Growth & Income) while trimming BlackRock ESG Term Trust, and Robinhood Markets sold ~$3.08M of Robinhood Ventures Fund I shares.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 30, 2026

The October 30, 2026 filing batch reveals a market defined by aggressive capital deployment and divergent earnings quality among Dow 30 constituents. Amazon's Q3 2026 results show a striking bifurcation: operating income surged 61.2% YoY to $28.1B on services strength, yet net income fell 2.4% as a $10.2B prior-year non-operating gain reversed, while nine-month capex ballooned to $175.7B (vs. $92.3B) and long-term debt proceeds hit $115.1B—signaling a debt-funded AI infrastructure bet that pressures near-term EPS. Chevron posted a massive YoY earnings rebound ($9.9B vs. $3.5B) on $97/bbl Brent and downstream recovery, but sequential earnings fell 18% and production slipped 2.6% YoY, while its balance sheet strengthened (debt-to-CFFO 0.6x vs. 1.3x). Three blue-chip issuers—Amex ($3.0B), P&G ($4.0B), and implicitly Amazon—tapped investment-grade markets, with P&G's curve topping out at 5.900% for 2056 paper, indicating elevated long-end rates. Insider activity was muted and slightly negative: an Alphabet director sold a small 10b5-1 tranche (~$23.3K). Vanguard's 13G in Nike (5.19% passive stake) is routine. Net: a capex-heavy, debt-funded growth cycle in tech contrasts with cash-generative energy and staples, creating relative-value opportunities and duration risk for bond-heavy balance sheets.

1 high priority 5 medium 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 30, 2026

A dense cluster of eight listing-standard deficiency notices filed within a single week (Oct 26-30, 2026) signals a broad-based microcap distress wave: five companies (Alset, Actuate, Neumora, Bridger Aerospace, and effectively Banzai) breached the $1.00 minimum bid price rule, while three (Accendra/Owens & Minor, Annovis Bio, Cyngn) face market-cap, equity, or governance-based deficiencies. The dominant theme is the reverse-stock-split playbook — Alset, Neumora, and Bridger all explicitly flagged splits as cure mechanisms, and Banzai paired its delisting notice with a same-day charter amendment to 850 million authorized shares, a classic recapitalization precursor. Balance-sheet severity varies widely: Annovis disclosed a stockholders' equity deficit of ~$(4.3) million against a $48.4 million market cap (just 3.2% below the $50 million NYSE threshold), whereas Accendra faces the more onerous NYSE 802.01B business-plan process with 18-month cure and quarterly monitoring. Actuate Therapeutics is the standout outlier with two concurrent Nasdaq deficiencies (bid price plus MVLS, the latter due January 11, 2027), creating a compressed dual-deadline risk profile. Notably, no filing disclosed insider buying, dividends, buybacks, or going-concern language — capital allocation is uniformly defensive, with equity issuance/dilution the only lever in play. The April 26, 2027 bid-price cure deadline is now a synchronized catalyst date across at least four names, setting up a Q1 2027 window of split announcements, potential delistings, and forced-selling dynamics.

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — October 30, 2026

The October 30, 2026 filing batch is dominated by distress and event-driven situations: insolvency proceedings (Tricom, Ushdev, BIL Vyapar, Videocon, Value Industries, MT Educare), delisting notices (Alset, Accendra/Owens & Minor, Annovis, Dynamix), and a completed Chapter 11 asset sale (BioXcel to Teva). M&A activity is bifurcated between large, transformative deals (Viatris' $1.46B tender for Pacira; First Financial's $111M merger with First Illinois) and numerous small, intra-group or nominal-value acquisitions (Waaree, Vimta, Juniper Green, Anup, Bharat Forge, Rane, Kajaria, Skipper, Apar, Aeroflex). Period comparisons show a stark divergence: GAIL posted 17.8% revenue growth and 109.7% net profit growth YoY, while Skipper's net profit rose 55.8% but total comprehensive income collapsed 84% due to reclassification items; Aeroflex swung to a net loss despite 3.5% revenue growth. Capital allocation is largely absent—no dividends or buybacks announced—except for tender offers (Ardian, Identiv, First Trust) and a preference share default at Blue Coast Hotels. Insider activity is minimal, but the related-party asset sale at Zoned Properties to its own CEO/CFO is a notable governance red flag. The batch signals a market where balance-sheet repair, delisting risk, and small-cap distress are prominent, while selective M&A and energy/industrial growth stories offer pockets of opportunity.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 30, 2026

Today's 50 SEC filings reveal a market defined by divergent earnings trajectories, aggressive capital deployment, and a clear rotation toward electrification and infrastructure. Q3 2026 results show revenue growth across most sectors, but margin pressure is pervasive: Cactus, Veralto, and LyondellBasell all reported cost increases outpacing revenue, compressing margins. In contrast, Regeneron and AstraZeneca delivered strong top-line beats, though both faced headwinds from legacy products and working capital. Capital allocation remains robust, with significant buybacks at GoDaddy ($1.3B), Regeneron ($2.3B), and ResMed ($936M), alongside strategic M&A in energy (Valero/LyondellBasell) and utilities (Alliant's 19% capex hike for data centers). Insider activity is notably absent from the enriched data, but 13F filings show institutional positioning heavily concentrated in mega-cap tech and ETFs, with some managers holding large cash-like positions. The most critical developments include Alliant's raised guidance and data center exposure, Valero's refinery acquisition, and the proposed Dominion-NextEra merger, which could reshape the utility landscape.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 30, 2026

The six filings reveal a consumer discretionary sector defined by aggressive platform expansion and capital intensity, offset by mixed earnings quality and selective insider selling. Amazon and DoorDash both delivered strong top-line growth (12.1% and 34% YoY, respectively), but Amazon's net income slipped 2.4% due to a prior-year non-operating gain reversal, while DoorDash's net income surged 91% YoY despite rising costs. Capital allocation is shifting toward debt-funded expansion: Amazon raised $115.1B in long-term debt and spent $175.7B on capex in nine months, while GM Financial issued $1.25B in senior notes. Insider activity is a notable negative signal, with Hilton's Kevin Jacobs selling $15.3M in stock after exercising options, suggesting potential valuation concerns. Institutional ownership changes are neutral, with Vanguard's 5.19% passive stake in Nike offering no directional signal. Overall, the sector shows a bifurcation between high-growth platforms investing heavily for future returns and mature companies facing margin pressures and insider distribution.

4 high priority 2 medium 6 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 30, 2026

The Q3 2026 healthcare earnings season reveals a sector grappling with patent cliffs, pipeline replenishment costs, and margin pressures, yet punctuated by standout growth stories. Regeneron (REGN) delivered a blowout quarter with revenue up 36.3% YoY to $5.1B, driven by Dupixent and EYLEA HD, but legacy EYLEA U.S. sales plunged 41%, highlighting the franchise transition risk. Gilead (GILD) posted a nine-month net loss of $6.0B due to $11.3B in acquired IPR&D, a stark reminder of the cost of replenishing its pipeline. AbbVie (ABBV) showed resilience with revenue up 10.3% and raised EPS guidance, but Humira and Imbruvica declines underscore its own patent challenges. Thermo Fisher (TMO) continued its steady growth (+9.1% revenue) and aggressive M&A ($8.9B YTD), while Stryker (SYK) saw profitability deteriorate with EPS down 11.7% on impairments and margin compression. Insider activity was mixed: a TMO director gifted shares and a C-level executive sold ~$2M, while Vanguard's passive stake in IDEXX crossed 5%. Overall, the sector faces a bifurcated landscape: innovative biopharma with strong growth but pipeline costs, and medtech with stable growth but margin headwinds.

7 high priority 3 medium 10 total filings
· daily

US Earnings Financial Results SEC Filings — October 30, 2026

Across 50 US SEC filings for the period ending 2026-10-30, revenue growth was robust but highly uneven: 32 companies reported YoY revenue increases (median +8.9%), while 18 reported declines, with the strongest growth in technology (Reddit +53%, Fortinet +20.5%, Intel +20.9%, Amazon +12.1%) and energy services (Cactus +63.2%, Mammoth +96.7%). Margin pressure was a dominant theme: 14 companies reported gross or operating margin compression, including ASGN (-130 bps gross margin), Veralto (operating margin 19.7% vs 23.2%), and Olin (operating income -28.5%), often due to rising SG&A, acquisition costs, or input inflation. Capital allocation remained aggressive: buybacks totaled over $4.5B across 12 companies (Amazon not included), with GoDaddy ($1.3B), ResMed ($936M), and Rocket ($709M net income) leading, while dividend increases were modest (WEC +42% EPS). Insider activity was notably absent from the enriched data, but management conviction can be inferred from buyback activity and guidance. Key risks emerged from impairment charges (Bright Horizons $290M, Intel $12.6B mark-to-market loss), credit deterioration (OFS Capital NAV -19.7%, SouthState provision +298%), and balance sheet stress (Mammoth cash -87%, Aware cash -67%). The overall picture suggests a late-cycle environment where revenue growth is slowing for many, cost control is critical, and balance sheet strength separates winners from losers.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 30, 2026

The 12 DEF 14A filings from October 30, 2026 reveal a broad market focus on governance, executive compensation, and strategic pivots, with several companies undergoing significant structural changes. Key themes include the termination of external management agreements (Cannae), merger-driven control shifts (Chemomab/Scipher), and charter amendments that could dilute common shareholders (Marwynn, Medicus). Executive compensation practices vary widely, from Tamboran's 35% increase in director fee pool to Stone Point's fee reduction contingent on proposal approvals. Insider ownership is highly concentrated in some cases (OpGen: 80.79% by directors/officers), raising governance concerns. Overall, filings are mostly routine but contain actionable insights for investors regarding upcoming votes, potential dilution, and strategic redirections.

12 high priority 12 total filings